

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.


Stephen C. D'Amico

Type or print name

*Stephen C. D'Amico*  
Signature

January 30, 2002

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 09/932,145

FILED: AUGUST 17, 2001

FOR: NOVEL IMIDAZOLINE RECEPTOR HOMOLOGS

**Attention: Box Missing Parts**

Assistant Commissioner for Patents

Washington, DC 20231

RESPONSE TO NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

Sir:

The Notice to File Missing Parts of Application - Filing Date Granted dated October 2, 2001  
(a copy of which is enclosed) has a shortened statutory time set to expire on December 2, 2001.

A two-month extension is hereby requested pursuant to 37 CFR §1.136(a). Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$400 for payment of the extension fee.

In response, applicants now submit an initial Computer Readable Form (CRF) of the Sequence Listing, an initial paper copy of the Sequence Listing and a Statement Verifying Identity of Above copies.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

02/15/2002 SDENBOB1 00000083 09932145


01 FC:116

400.00 CH

A duplicate copy of this letter is provided for charging purposes.

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: January 30, 2002

  
\_\_\_\_\_  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/932,145	08/17/2001	John N. Feder	D0020 PSP

Christopher A. Klein, Esq.  
Bristol-Myers Squibb Company  
Post Office Box 4000  
Lawrenceville-Provinceline Road  
Princeton, NJ 08543-4000

<b>RECEIVED</b> <b>U.S. Patent Law</b>  <b>JAN 22 2002</b>	
Docketed Item	_____
Due Date	_____
Attorney	_____

CONFIRMATION NO. 5154

FORMALITIES LETTER



\*OC00000007309754\*

Date Mailed: 01/15/2002

**NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)***Filing Date Granted*

The U.S. Patent and Trademark Office has received your reply on 01/03/2002 to the Notice to File Missing Parts (Notice) mailed 10/02/2001 and it has been entered into the nonprovisional application. The reply, however, does not include the following items required in the Notice.

The period of reply remains as set forth in the Notice. You may, however, obtain EXTENSIONS OF TIME under the provisions of 37 CFR 1.136 (a) accompanied by the appropriate fee (37 CFR 1.17(a)).

A complete reply must be timely filed to prevent ABANDONMENT of the above-identified application.

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

02/15/2002 SDENB031 00000003 193800 00932145

01/15/02

030.00 01

***A copy of this notice MUST be returned with the reply.***




+7  
CASE D0020 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico  
Type or print name

  
Signature

January 30, 2002  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 09/932,145

FILED: AUGUST 17, 2001

FOR: NOVEL IMIDAZOLINE RECEPTOR HOMOLOGS

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING INCLUDING STATEMENT OF  
VERIFICATION IN RESPONSE TO NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)


Sir:

In response to the Notice of Incomplete Reply (NonProvisional), the Sequence Listing is enclosed to make it compliant with C.F.R. 1.821-1.825. Respectfully, no new matter has been added.

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5289  
Date: January 30, 2002

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652